TRANSCODE THERAPEUTICS INC (RNAZ)

NASDAQHealth CareBiotechnologySnapshot 2026-09-04

$2.06-4.19%

Close 2026-09-04 · 1-day change

QuarterlyIQ Insights · RNAZ

Financials

Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.

Income Statement

Period

View

Order

Figures in millions of None, except per-share and ratios.

	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Operating Expenses & Income
R&D Expenses	17.4	13.4	9.7	12.3	10.2	2.8	0.3
Operating Income	(45.1)	(28.0)	(15.7)	(19.4)	(18.6)	(6.2)	(0.7)
Earnings from Continuing Operations
Interest Expense	—	0.0	0.0	0.1	0.0	0.1	0.4
Interest & Investment Income	0.2	0.1	0.0	0.0	0.0	0.0	0.0
Net Interest Expenses	—	—	—	0.1	0.0	0.1	0.4
Other Non-Operating Income / Expenses	2.8	(6.5)	(1.1)	0.9	1.1	(0.7)	(1.6)
EBT, Incl. Unusual Items	—	(34.4)	—	—	—	—	—
Income Tax Expense	—	0.2	0.0	0.0	0.0	0.1	0.0
Net Income
Net Income	(42.8)	(34.7)	(16.8)	(18.5)	(17.6)	(6.8)	(2.3)
Per Share
Basic EPS	(44.75)	(52.59)	(47.14)	—	—	(0.81)	(0.51)
Diluted EPS	(44.75)	(52.59)	(47.14)	—	—	(0.81)	(0.51)
Basic Weighted Avg Shares	1.0	0.7	0.4	0.0	0.0	8.4	4.6
Diluted Weighted Avg Shares	1.0	0.7	0.4	0.0	0.0	8.4	4.6
Supplemental
EBITDA	—	(27.9)	(15.6)	(19.3)	(18.5)	(6.1)	(0.7)
EBIT	(45.1)	(28.0)	(15.7)	(19.4)	(18.6)	(6.2)	(0.7)

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.